A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia

Acute myeloid leukemia (AML), the most common adult acute leukemia in the United States, has the poorest survival rate, with 26% of patients surviving 5 years. Adoptive immunotherapy with T cells genetically modified to recognize tumors is a promising and evolving treatment option. However, antitumo...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 130; no. 22; p. 2410
Main Authors:	Oda, Shannon K, Daman, Andrew W, Garcia, Nicolas M, Wagener, Felecia, Schmitt, Thomas M, Tan, Xiaoxia, Chapuis, Aude G, Greenberg, Philip D
Format:	Journal Article
Language:	English
Published:	United States 30.11.2017
Subjects:	Animals Antigens, Surface - genetics Antigens, Surface - immunology CD28 Antigens - genetics CD28 Antigens - immunology Cell Proliferation Humans Immunomodulation Immunotherapy, Adoptive - methods Leukemia - genetics Leukemia - immunology Leukemia - therapy Membrane Glycoproteins - genetics Membrane Glycoproteins - immunology Mice Mice, Inbred C57BL Mice, Transgenic Orexin Receptors Receptors, Cell Surface - genetics Receptors, Cell Surface - immunology Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology T-Lymphocytes - immunology T-Lymphocytes - metabolism T-Lymphocytes - transplantation Transduction, Genetic
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!